figure1

This is the second study published in Nature that demonstrates cross-reactive T-cell immunity. I mentioned the other one here.

This one (SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition) says:

Cross-reactive SARS-CoV-2 peptides revealed pre-existing T cell responses in 81% of unexposed individuals and validated similarity with common cold coronaviruses, providing a functional basis for heterologous immunity in SARS-CoV-2 infection.